Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 241

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective

Open access
Austin, Christopher P., Cutillo, Christine M., Lau, Lilian P.L., Jonker, Anneliene H., Rath, Ana, Julkowska, Daria, Thomson, David, Terry, Sharon F., de Montleau, Béatrice, Ardigò, Diego, Hivert, Virginie, Boycott, Kym M., Baynam, Gareth, Kaufmann, Petra, Taruscio, Domenica, Lochmüller, Hanns, Suematsu, Makoto, Incerti, Carlo, Draghia‐Akli, Ruxandra, Norstedt, Irene, Wang, Lu, Dawkins, Hugh J.S., on behalf of the International Rare Diseases Research Consortium (IRDiRC) · 2018 · Clinical and Translational Science

Abstract

The International Rare Diseases Research Consortium (IRDiRC) was founded in 2011 with the conviction that rare diseases research had reached a critical juncture.Proof of principle existed that rare diseases could be diagnosed, new treatments successfully developed and approved, and improvements in quality and quantity of life achieved.Government research funders, companies, scientists, and patient advocacy groups had all demonstrated their commitment and effectiveness in contributing to progress in rare diseases research.However, the work was largely atomized, with each organization, each country, and the champions of each disease pursuing independent, often duplicative solutions.The scale of the "rare disease problem"-thousands of rare diseases, the vast preponderance of them with no approved treatment, and decades-long diagnostic odysseys for many patients-led to the realization that the time had arrived for global cooperation and collaboration among the many stakeholders active in rare diseases research, to capitalize on these proofs of principle, and maximize the output of rare diseases research efforts around the world.IRDiRC's initial aims were to aid in the achievement of two overarching objectives: to contribute to the development of 200 new therapies and the means to diagnose most rare diseases by the year 2020. 1 For more detailed information on the history, governance, and nascent stages of the Consortium, please refer to the accompanying piece on the first 6 years of IRDiRC. 2 Due to the remarkable global surge in activity in rare diseases research over the last 6 years, including contributions by IRDiRC, the Consortium's 2020 goal for 200 new therapies was achieved in early 2017-3 years ahead of scheduleand the goal for diagnostics-the ability to diagnose most rare diseases by 2020-is within reach; these accomplishments were celebrated at the 3 rd IRDiRC Conference in Paris

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cts.12500

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 241

Metadata

Authors
Austin, C. P., Cutillo, C. M., Lau, L. P. L., Jonker, A. H., Rath, A., Julkowska, D., Thomson, D., Terry, S. F., de Montleau, B., Ardigò, D., Hivert, V., Boycott, K. M., Baynam, G., Kaufmann, P., Taruscio, D., Lochmüller, H., Suematsu, M., Incerti, C., Draghia‐Akli, R., Norstedt, I., Wang, L., Dawkins, H. J. S., & on behalf of the International Rare Diseases Research Consortium (IRDiRC)
Venue
Clinical and Translational Science
Publisher
Wiley
Published
2017-10-23
Volume
11
Issue
1
Pages
21-27
ISSN
  • 1752-8054 (ISSN-L)
  • 1752-8062
OpenAlex
W2744672018
Cited by
241
References
3
FWCI
11.78
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.